Search Results

You are looking at 1 - 10 of 16 items for

  • Author: Claes Ohlsson x
  • Refine by access: Content accessible to me x
Clear All Modify Search
Maryam Iravani Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden

Search for other papers by Maryam Iravani in
Google Scholar
PubMed
Close
,
Marie Lagerquist Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Search for other papers by Marie Lagerquist in
Google Scholar
PubMed
Close
,
Claes Ohlsson Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Close
, and
Lars Sävendahl Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden

Search for other papers by Lars Sävendahl in
Google Scholar
PubMed
Close

Estrogens are well known for their capacity to promote bone maturation and at high doses to induce growth plate closure and thereby stop further growth. High-dose estrogen treatment has therefore been used to limit growth in extremely tall girls. However, recent data suggest that this treatment may have severe side effects, including increased risk of cancer and reduced fertility. We hypothesized that estrogenic effects in bone are mediated via ERα signaling. Twelve-week-old ovariectomized female C57BL/6 mice were subcutaneously injected for 4 weeks with E2 or selective ERα (PPT) or ERβ (DPN) agonists. After killing, tibia and femur lengths were measured, and growth plate morphology was analyzed. E2- and PPT-treated mice had shorter tibiae and femur bones when compared to vehicle-treated controls, whereas animals treated with DPN had similar bone lengths compared to controls. Growth plate height and hypertrophic zone height were reduced in animals treated with E2 or PPT but not in those treated with DPN, supporting that the effect was mediated via ERα. Moreover, PCNA staining revealed suppressed proliferation of chondrocytes in the tibia growth plate in PPT- or E2-treated mice compared to controls. Our data show that estrogenic effects on bone growth and growth plate maturation are mainly mediated via ERα. Our findings may have direct implications for the development of new and more selective treatment modalities of extreme tall stature using selective estrogen receptor modulators that may have low side effects than high-dose E2 treatment.

Free access
Louise Grahnemo Departments of Rheumatology and Inflammation Research, Internal Medicine and Clinical Nutrition, Laboratory of Tumor Immunology and Biology, Centre for Bone and Arthritis Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Box 480, Gothenburg 405 30, Sweden

Search for other papers by Louise Grahnemo in
Google Scholar
PubMed
Close
,
Caroline Jochems Departments of Rheumatology and Inflammation Research, Internal Medicine and Clinical Nutrition, Laboratory of Tumor Immunology and Biology, Centre for Bone and Arthritis Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Box 480, Gothenburg 405 30, Sweden
Departments of Rheumatology and Inflammation Research, Internal Medicine and Clinical Nutrition, Laboratory of Tumor Immunology and Biology, Centre for Bone and Arthritis Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Box 480, Gothenburg 405 30, Sweden

Search for other papers by Caroline Jochems in
Google Scholar
PubMed
Close
,
Annica Andersson Departments of Rheumatology and Inflammation Research, Internal Medicine and Clinical Nutrition, Laboratory of Tumor Immunology and Biology, Centre for Bone and Arthritis Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Box 480, Gothenburg 405 30, Sweden

Search for other papers by Annica Andersson in
Google Scholar
PubMed
Close
,
Cecilia Engdahl Departments of Rheumatology and Inflammation Research, Internal Medicine and Clinical Nutrition, Laboratory of Tumor Immunology and Biology, Centre for Bone and Arthritis Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Box 480, Gothenburg 405 30, Sweden
Departments of Rheumatology and Inflammation Research, Internal Medicine and Clinical Nutrition, Laboratory of Tumor Immunology and Biology, Centre for Bone and Arthritis Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Box 480, Gothenburg 405 30, Sweden

Search for other papers by Cecilia Engdahl in
Google Scholar
PubMed
Close
,
Claes Ohlsson Departments of Rheumatology and Inflammation Research, Internal Medicine and Clinical Nutrition, Laboratory of Tumor Immunology and Biology, Centre for Bone and Arthritis Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Box 480, Gothenburg 405 30, Sweden

Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Close
,
Ulrika Islander Departments of Rheumatology and Inflammation Research, Internal Medicine and Clinical Nutrition, Laboratory of Tumor Immunology and Biology, Centre for Bone and Arthritis Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Box 480, Gothenburg 405 30, Sweden

Search for other papers by Ulrika Islander in
Google Scholar
PubMed
Close
, and
Hans Carlsten Departments of Rheumatology and Inflammation Research, Internal Medicine and Clinical Nutrition, Laboratory of Tumor Immunology and Biology, Centre for Bone and Arthritis Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Box 480, Gothenburg 405 30, Sweden

Search for other papers by Hans Carlsten in
Google Scholar
PubMed
Close

Treatment with anti-inflammatory glucocorticoids is associated with osteoporosis. Many of the treated patients are postmenopausal women, who even without treatment have an increased risk of osteoporosis. Lymphocytes have been shown to play a role in postmenopausal and arthritis-induced osteoporosis, and they are targeted by glucocorticoids. The aim of this study was to investigate the mechanisms behind effects of glucocorticoids on bone during health and menopause, focusing on lymphocytes. Female C57BL/6 or SCID mice were therefore sham-operated or ovariectomized and 2 weeks later treatment with dexamethasone (dex), the nonsteroidal anti-inflammatory drug carprofen, or vehicle was started and continued for 2.5 weeks. At the termination of experiments, femurs were phenotyped using peripheral quantitative computed tomography and high-resolution micro-computed tomography, and markers of bone turnover were analyzed in serum. T and B lymphocyte populations in bone marrow and spleen were analyzed by flow cytometry. Dex-treated C57BL/6 mice had increased trabecular bone mineral density, but lower cortical content and thickness compared with vehicle-treated mice. The dex-treated mice also had lower levels of bone turnover markers and markedly decreased numbers of spleen T and B lymphocytes. In contrast, these effects could not be repeated when mice were treated with the nonsteroidal anti-inflammatory drug carprofen. In addition, dex did not increase trabecular bone in ovariectomized SCID mice lacking functional T and B lymphocytes. In contrast to most literature, the results from this study indicate that treatment with dex increased trabecular bone density, which may indicate that this effect is associated with corticosteroid-induced alterations of the lymphocyte populations.

Open access
Lovisa Lundholm
Search for other papers by Lovisa Lundholm in
Google Scholar
PubMed
Close
,
Milica Putnik
Search for other papers by Milica Putnik in
Google Scholar
PubMed
Close
,
Michio Otsuki Department of Biosciences and Nutrition at Novum, Department of Medicine, Division of Endocrinology, Karolinska Institutet, SE-141 57 Huddinge, Sweden

Search for other papers by Michio Otsuki in
Google Scholar
PubMed
Close
,
Sandra Andersson
Search for other papers by Sandra Andersson in
Google Scholar
PubMed
Close
,
Claes Ohlsson Department of Biosciences and Nutrition at Novum, Department of Medicine, Division of Endocrinology, Karolinska Institutet, SE-141 57 Huddinge, Sweden

Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Close
,
Jan-Åke Gustafsson
Search for other papers by Jan-Åke Gustafsson in
Google Scholar
PubMed
Close
, and
Karin Dahlman-Wright
Search for other papers by Karin Dahlman-Wright in
Google Scholar
PubMed
Close

Obesity has become a major health problem in many parts of the world. Estrogens are known to reduce adipose tissue mass in both humans and animals but the molecular mechanisms are not well characterized. We used gene expression profiling to study long-term effects of estrogen on gene expression in mouse white adipose tissue and hypothalamus. Overall, the effects of estrogen on hypothalamic gene expression were much smaller than the corresponding effects on white adipose tissue gene expression. We characterize in detail estrogenic regulation of glutathione peroxidase 3 (GPX3). Our studies suggest that GPX3 is a direct estrogen receptor α target gene in white adipose tissue. Since obesity is correlated with oxidative stress, and GPX3 has been demonstrated to be lower in obesity and higher after weight loss, we hypothesize that GPX3 is one important mediator of effects of estrogen in relation to fat mass. Additional genes that were affected by estrogen in adipose tissue include cell death-inducing DNA fragmentation factor, α-subunit-like effector A (CIDEA), a gene shown to be related to body fat in mice. We conclude that estrogen has large effects on gene expression in white adipose tissue and hypothesize that GPX3 and CIDEA could be important mediators of the effects of estrogen on fat mass.

Free access
Thomas Funck-Brentano Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Thomas Funck-Brentano in
Google Scholar
PubMed
Close
,
Karin H Nilsson Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Karin H Nilsson in
Google Scholar
PubMed
Close
,
Robert Brommage Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Robert Brommage in
Google Scholar
PubMed
Close
,
Petra Henning Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Petra Henning in
Google Scholar
PubMed
Close
,
Ulf H Lerner Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Ulf H Lerner in
Google Scholar
PubMed
Close
,
Antti Koskela Unit of Cancer Research and Translational Medicine, MRC Oulu and Department of Anatomy and Cell Biology, University of Oulu, Oulu, Finland

Search for other papers by Antti Koskela in
Google Scholar
PubMed
Close
,
Juha Tuukkanen Unit of Cancer Research and Translational Medicine, MRC Oulu and Department of Anatomy and Cell Biology, University of Oulu, Oulu, Finland

Search for other papers by Juha Tuukkanen in
Google Scholar
PubMed
Close
,
Martine Cohen-Solal BIOSCAR UMRS 1132, Université Paris Diderot, Sorbonne Paris Cité, INSERM, Paris, France

Search for other papers by Martine Cohen-Solal in
Google Scholar
PubMed
Close
,
Sofia Movérare-Skrtic Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Sofia Movérare-Skrtic in
Google Scholar
PubMed
Close
, and
Claes Ohlsson Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Close

WNT signaling is involved in the tumorigenesis of various cancers and regulates bone homeostasis. Palmitoleoylation of WNTs by Porcupine is required for WNT activity. Porcupine inhibitors are under development for cancer therapy. As the possible side effects of Porcupine inhibitors on bone health are unknown, we determined their effects on bone mass and strength. Twelve-week-old C57BL/6N female mice were treated by the Porcupine inhibitors LGK974 (low dose = 3 mg/kg/day; high dose = 6 mg/kg/day) or Wnt-C59 (10 mg/kg/day) or vehicle for 3 weeks. Bone parameters were assessed by serum biomarkers, dual-energy X-ray absorptiometry, µCT and histomorphometry. Bone strength was measured by the 3-point bending test. The Porcupine inhibitors were well tolerated demonstrated by normal body weight. Both doses of LGK974 and Wnt-C59 reduced total body bone mineral density compared with vehicle treatment (P < 0.001). Cortical thickness of the femur shaft (P < 0.001) and trabecular bone volume fraction in the vertebral body (P < 0.001) were reduced by treatment with LGK974 or Wnt-C59. Porcupine inhibition reduced bone strength in the tibia (P < 0.05). The cortical bone loss was the result of impaired periosteal bone formation and increased endocortical bone resorption and the trabecular bone loss was caused by reduced trabecular bone formation and increased bone resorption. Porcupine inhibitors exert deleterious effects on bone mass and strength caused by a combination of reduced bone formation and increased bone resorption. We suggest that cancer targeted therapies using Porcupine inhibitors may increase the risk of fractures.

Open access
Lina Lawenius Sahlgrenska Osteoporosis Centre and Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Lina Lawenius in
Google Scholar
PubMed
Close
,
Hannah Colldén Sahlgrenska Osteoporosis Centre and Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Hannah Colldén in
Google Scholar
PubMed
Close
,
Karin Horkeby Sahlgrenska Osteoporosis Centre and Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Karin Horkeby in
Google Scholar
PubMed
Close
,
Jianyao Wu Sahlgrenska Osteoporosis Centre and Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Jianyao Wu in
Google Scholar
PubMed
Close
,
Louise Grahnemo Sahlgrenska Osteoporosis Centre and Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Louise Grahnemo in
Google Scholar
PubMed
Close
,
Liesbeth Vandenput Sahlgrenska Osteoporosis Centre and Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia

Search for other papers by Liesbeth Vandenput in
Google Scholar
PubMed
Close
,
Claes Ohlsson Sahlgrenska Osteoporosis Centre and Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Close
, and
Klara Sjögren Sahlgrenska Osteoporosis Centre and Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Klara Sjögren in
Google Scholar
PubMed
Close

Studies in postmenopausal women and ovariectomized mice show that the probiotic mix Lacticaseibacillus paracasei DSM13434, Lactiplantibacillus plantarum DSM 15312 and DSM 15313 (L. Mix) can protect from bone loss caused by sex steroid deficiency. Whether probiotic bacteria can protect bone also in sex steroid-deficient males is less studied. We used the orchiectomized mouse as a model for age-dependent bone loss caused by decreasing sex hormone levels in males. We treated 10-week-old male mice with either vehicle (veh) or L. Mix for 6 weeks, starting 2 weeks before orchiectomy (orx) or sham surgery. Importantly, mice treated with L. Mix had a general increase in total body bone mineral density (BMD) and lean mass (P ≤ 0.05) compared with veh-treated mice. Detailed computer tomography analysis of dissected bones showed increased trabecular BMD of the distal metaphyseal region of the femur in L. Mix compared to veh-treated orx mice (+8.0%, P ≤ 0.05). In the vertebra, L. Mix treatment increased trabecular bone volume fraction BV/TV (+11.5%, P ≤ 0.05) compared to veh in orx mice. Also, L. Mix increased the levels of short-chain fatty acids (SCFAs) such as propionate and acetate and important intermediates in SCFA synthesis such as succinate and lactate in the cecal content of male mice. In conclusion, L. Mix treatment resulted in a general increase in BMD in adult male mice and prevented trabecular bone loss in femur and vertebra of orx mice. These bone protective effects of L. Mix were associated with increased levels of SCFAs in the cecal content of male mice.

Open access
Åsa Tivesten
Search for other papers by Åsa Tivesten in
Google Scholar
PubMed
Close
,
Anna Barlind
Search for other papers by Anna Barlind in
Google Scholar
PubMed
Close
,
Kenneth Caidahl
Search for other papers by Kenneth Caidahl in
Google Scholar
PubMed
Close
,
Natalia Klintland
Search for other papers by Natalia Klintland in
Google Scholar
PubMed
Close
,
Antonio Cittadini
Search for other papers by Antonio Cittadini in
Google Scholar
PubMed
Close
,
Claes Ohlsson
Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Close
, and
Jörgen Isgaard
Search for other papers by Jörgen Isgaard in
Google Scholar
PubMed
Close

Growth hormone (GH) deficiency is associated with abnormal vascular reactivity and development of atherosclerosis. GH treatment in GH deficient states restores systemic vascular resistance, arterial compliance, endothelium-dependent and endothelium-independent vasodilation, and may reverse markers of early atherosclerosis. However, very little is known about the molecular mechanisms underlying these effects. In the present study, male Sprague Dawley rats were hypophysectomized and treated for two weeks with GH (recombinant human GH, 2 mg/kg/day) or saline as s.c. injections twice daily. GH decreased aortic systolic blood pressure compared with saline-treated animals, while the diastolic blood pressure was not significantly changed. GH treatment increased cardiac output as determined by Doppler-echocardiography and the calculated systemic vascular resistance was markedly reduced. In order to identify GH-regulated genes of importance for vascular function, aortic mRNA levels were analyzed by the microarray technique and correlated to the systolic blood pressure levels. Using this approach, we identified 18 GH-regulated genes with possible impact on vascular tone and atherogenesis. In particular, mRNA levels of the inwardly rectifying potassium channel Kir6.1 and the sulfonylurea receptor 2B, which together form the vascular smooth muscle ATP-sensitive potassium channel, were both up-regulated by GH treatment and highly correlated to systolic blood pressure. Our findings establish a major role for GH in the regulation of vascular physiology and gene expression. Increased expression of the ATP-sensitive potassium channel, recently shown to be crucial in the regulation of vascular tone, constitutes a possible mechanism by which GH governs vascular tone.

Free access
Joyce Emons
Search for other papers by Joyce Emons in
Google Scholar
PubMed
Close
,
Andrei S Chagin Department of Paediatrics, Department of Women's and Children's Health, Division of Endocrinology, Department of Tissue Regeneration, Department of Endocrinology and Metabolism, Leiden University Medical Center, 2300 ZA Leiden, The Netherlands

Search for other papers by Andrei S Chagin in
Google Scholar
PubMed
Close
,
Torun Malmlöf Department of Paediatrics, Department of Women's and Children's Health, Division of Endocrinology, Department of Tissue Regeneration, Department of Endocrinology and Metabolism, Leiden University Medical Center, 2300 ZA Leiden, The Netherlands

Search for other papers by Torun Malmlöf in
Google Scholar
PubMed
Close
,
Magnus Lekman Department of Paediatrics, Department of Women's and Children's Health, Division of Endocrinology, Department of Tissue Regeneration, Department of Endocrinology and Metabolism, Leiden University Medical Center, 2300 ZA Leiden, The Netherlands

Search for other papers by Magnus Lekman in
Google Scholar
PubMed
Close
,
Åsa Tivesten Department of Paediatrics, Department of Women's and Children's Health, Division of Endocrinology, Department of Tissue Regeneration, Department of Endocrinology and Metabolism, Leiden University Medical Center, 2300 ZA Leiden, The Netherlands

Search for other papers by Åsa Tivesten in
Google Scholar
PubMed
Close
,
Claes Ohlsson Department of Paediatrics, Department of Women's and Children's Health, Division of Endocrinology, Department of Tissue Regeneration, Department of Endocrinology and Metabolism, Leiden University Medical Center, 2300 ZA Leiden, The Netherlands

Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Close
,
Jan M Wit
Search for other papers by Jan M Wit in
Google Scholar
PubMed
Close
,
Marcel Karperien Department of Paediatrics, Department of Women's and Children's Health, Division of Endocrinology, Department of Tissue Regeneration, Department of Endocrinology and Metabolism, Leiden University Medical Center, 2300 ZA Leiden, The Netherlands
Department of Paediatrics, Department of Women's and Children's Health, Division of Endocrinology, Department of Tissue Regeneration, Department of Endocrinology and Metabolism, Leiden University Medical Center, 2300 ZA Leiden, The Netherlands

Search for other papers by Marcel Karperien in
Google Scholar
PubMed
Close
, and
Lars Sävendahl Department of Paediatrics, Department of Women's and Children's Health, Division of Endocrinology, Department of Tissue Regeneration, Department of Endocrinology and Metabolism, Leiden University Medical Center, 2300 ZA Leiden, The Netherlands

Search for other papers by Lars Sävendahl in
Google Scholar
PubMed
Close

Longitudinal bone growth is regulated in the growth plate. At the end of puberty, growth velocity diminishes and eventually ceases with the fusion of the growth plate through mechanisms that are not yet completely understood. Vascular endothelial growth factor (VEGF) has an important role in angiogenesis, but also in chondrocyte differentiation, chondrocyte survival, and the final stages of endochondral ossification. Estrogens have been shown to up-regulate VEGF expression in the uterus and bone of rats. In this study, we investigated the relation between estrogens and VEGF production in growth plate chondrocytes both in vivo and in vitro. The expression of VEGF protein was down-regulated upon ovariectomy and was restored upon estradiol (E2) supplementation in rat growth plates. In cultured rat chondrocyte cell line RCJ3.1C5.18, E2 dose dependently stimulated 121 and 189 kDa isoforms of VEGF, but not the 164 kDa isoform. Finally, VEGF expression was observed at both protein and mRNA levels in human growth plate specimens. The protein level increased during pubertal development, supporting a link between estrogens and local VEGF production in the growth plate. We conclude that estrogens regulate VEGF expression in the epiphyseal growth plate, although the precise role of VEGF in estrogen-mediated growth plate fusion remains to be clarified.

Free access
Johan Svensson Department of Internal Medicine, Sahlgrenska University Hospital, Gröna Stråket 8, SE-413 45 Göteborg, Sweden
Department of Clinical Physiology, Göteborg University, Göteborg, Sweden
Musculoskeletal Disease Center, Jerry L Pettis Memorial VA Medical Center, Loma Linda, California, USA
Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden

Search for other papers by Johan Svensson in
Google Scholar
PubMed
Close
,
Åsa Tivesten Department of Internal Medicine, Sahlgrenska University Hospital, Gröna Stråket 8, SE-413 45 Göteborg, Sweden
Department of Clinical Physiology, Göteborg University, Göteborg, Sweden
Musculoskeletal Disease Center, Jerry L Pettis Memorial VA Medical Center, Loma Linda, California, USA
Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden

Search for other papers by Åsa Tivesten in
Google Scholar
PubMed
Close
,
Klara Sjögren Department of Internal Medicine, Sahlgrenska University Hospital, Gröna Stråket 8, SE-413 45 Göteborg, Sweden
Department of Clinical Physiology, Göteborg University, Göteborg, Sweden
Musculoskeletal Disease Center, Jerry L Pettis Memorial VA Medical Center, Loma Linda, California, USA
Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden

Search for other papers by Klara Sjögren in
Google Scholar
PubMed
Close
,
Olle Isaksson Department of Internal Medicine, Sahlgrenska University Hospital, Gröna Stråket 8, SE-413 45 Göteborg, Sweden
Department of Clinical Physiology, Göteborg University, Göteborg, Sweden
Musculoskeletal Disease Center, Jerry L Pettis Memorial VA Medical Center, Loma Linda, California, USA
Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden

Search for other papers by Olle Isaksson in
Google Scholar
PubMed
Close
,
Göran Bergström Department of Internal Medicine, Sahlgrenska University Hospital, Gröna Stråket 8, SE-413 45 Göteborg, Sweden
Department of Clinical Physiology, Göteborg University, Göteborg, Sweden
Musculoskeletal Disease Center, Jerry L Pettis Memorial VA Medical Center, Loma Linda, California, USA
Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden

Search for other papers by Göran Bergström in
Google Scholar
PubMed
Close
,
Subburaman Mohan Department of Internal Medicine, Sahlgrenska University Hospital, Gröna Stråket 8, SE-413 45 Göteborg, Sweden
Department of Clinical Physiology, Göteborg University, Göteborg, Sweden
Musculoskeletal Disease Center, Jerry L Pettis Memorial VA Medical Center, Loma Linda, California, USA
Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden

Search for other papers by Subburaman Mohan in
Google Scholar
PubMed
Close
,
Johan Mölne Department of Internal Medicine, Sahlgrenska University Hospital, Gröna Stråket 8, SE-413 45 Göteborg, Sweden
Department of Clinical Physiology, Göteborg University, Göteborg, Sweden
Musculoskeletal Disease Center, Jerry L Pettis Memorial VA Medical Center, Loma Linda, California, USA
Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden

Search for other papers by Johan Mölne in
Google Scholar
PubMed
Close
,
Jörgen Isgaard Department of Internal Medicine, Sahlgrenska University Hospital, Gröna Stråket 8, SE-413 45 Göteborg, Sweden
Department of Clinical Physiology, Göteborg University, Göteborg, Sweden
Musculoskeletal Disease Center, Jerry L Pettis Memorial VA Medical Center, Loma Linda, California, USA
Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden

Search for other papers by Jörgen Isgaard in
Google Scholar
PubMed
Close
, and
Claes Ohlsson Department of Internal Medicine, Sahlgrenska University Hospital, Gröna Stråket 8, SE-413 45 Göteborg, Sweden
Department of Clinical Physiology, Göteborg University, Göteborg, Sweden
Musculoskeletal Disease Center, Jerry L Pettis Memorial VA Medical Center, Loma Linda, California, USA
Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden

Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Close

The GH/-IGF-I axis is important for kidney size and function and may also be involved in the development of renal failure. In this study, the role of liver-derived endocrine IGF-I for kidney size and function was investigated in mice with adult liver-specific IGF-I inactivation (LI-IGF-I−/− mice). These mice have an 80–85% reduction of serum IGF-I level and compensatory increased GH secretion. Seven-month-old as well as 24-month-old LI-IGF-I−/− mice had decreased kidney weight. Glomerular filtration rate, assessed using creatinine clearance as well as creatinine clearance corrected for body weight, was unchanged. The 24-h urine excretion of sodium and potassium was increased in the LI-IGF-I−/− mice. In the 24-month-old mice, there was no between-group difference in kidney morphology. Microarray and real-time PCR (RT-PCR) analyses showed a high renal expression of IGF-II in the control mice, whereas in the LI-IGF-I−/− mice, there was a tissue-specific decrease in the renal IGF-II mRNA levels (−79%, P < 0.001 vs controls using RT-PCR). In conclusion, deficiency of circulating liver-derived IGF-I in mice results, despite an increase in GH secretion, in a global symmetrical decrease in kidney size, increased urinary sodium and potassium excretion, and a clear down regulation of renal IGF-II expression. However, the LI-IGF-I−/− mice did not develop kidney failure or nephrosclerosis. One may speculate that liver-derived endocrine IGF-I induces renal IGF-II expression, resulting in symmetrical renal growth.

Free access
Annica Andersson Centre for Bone and Arthritis Research, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Annica Andersson in
Google Scholar
PubMed
Close
,
Anna E Törnqvist Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Anna E Törnqvist in
Google Scholar
PubMed
Close
,
Sofia Moverare-Skrtic Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Sofia Moverare-Skrtic in
Google Scholar
PubMed
Close
,
Angelina I Bernardi Centre for Bone and Arthritis Research, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Angelina I Bernardi in
Google Scholar
PubMed
Close
,
Helen H Farman Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Helen H Farman in
Google Scholar
PubMed
Close
,
Pierre Chambon Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, National de la Sante et de la Recherche Medicale, ULP, Collège de France, Illkirch-Strasbourg, France

Search for other papers by Pierre Chambon in
Google Scholar
PubMed
Close
,
Cecilia Engdahl Centre for Bone and Arthritis Research, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Cecilia Engdahl in
Google Scholar
PubMed
Close
,
Marie K Lagerquist Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Marie K Lagerquist in
Google Scholar
PubMed
Close
,
Sara H Windahl Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Sara H Windahl in
Google Scholar
PubMed
Close
,
Hans Carlsten Centre for Bone and Arthritis Research, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Hans Carlsten in
Google Scholar
PubMed
Close
,
Claes Ohlsson Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Close
, and
Ulrika Islander Centre for Bone and Arthritis Research, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Ulrika Islander in
Google Scholar
PubMed
Close

Apart from the role of sex steroids in reproduction, sex steroids are also important regulators of the immune system. 17β-estradiol (E2) represses T and B cell development, but augments B cell function, possibly explaining the different nature of immune responses in men and women. Both E2 and selective estrogen receptors modulators (SERM) act via estrogen receptors (ER). Activating functions (AF)-1 and 2 of the ER bind to coregulators and thus influence target gene transcription and subsequent cellular response to ER activation. The importance of ERαAF-1 and AF-2 in the immunomodulatory effects of E2/SERM has previously not been reported. Thus, detailed studies of T and B lymphopoiesis were performed in ovariectomized E2-, lasofoxifene- or raloxifene-treated mice lacking either AF-1 or AF-2 domains of ERα, and their wild-type littermate controls. Immune cell phenotypes were analyzed with flow cytometry. All E2 and SERM-mediated inhibitory effects on thymus cellularity and thymic T cell development were clearly dependent on both ERαAFs. Interestingly, divergent roles of ERαAF-1 and ERαAF-2 in E2 and SERM-mediated modulation of bone marrow B lymphopoiesis were found. In contrast to E2, effects of lasofoxifene on early B cells did not require functional ERαAF-2, while ERαAF-1 was indispensable. Raloxifene reduced early B cells partly independent of both ERαAF-1 and ERαAF-2. Results from this study increase the understanding of the impact of ER modulation on the immune system, which can be useful in the clarification of the molecular actions of SERMs and in the development of new SERM.

Free access
Vikte Lionikaite Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute for Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Search for other papers by Vikte Lionikaite in
Google Scholar
PubMed
Close
,
Karin L Gustafsson Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute for Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Search for other papers by Karin L Gustafsson in
Google Scholar
PubMed
Close
,
Anna Westerlund Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute for Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Search for other papers by Anna Westerlund in
Google Scholar
PubMed
Close
,
Sara H Windahl Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute for Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Search for other papers by Sara H Windahl in
Google Scholar
PubMed
Close
,
Antti Koskela Department of Anatomy and Cell Biology, Medical Research Center, University of Oulu, Oulu, Finland

Search for other papers by Antti Koskela in
Google Scholar
PubMed
Close
,
Juha Tuukkanen Department of Anatomy and Cell Biology, Medical Research Center, University of Oulu, Oulu, Finland

Search for other papers by Juha Tuukkanen in
Google Scholar
PubMed
Close
,
Helena Johansson Institute for Health and Aging, Catholic University of Australia, Melbourne, Australia

Search for other papers by Helena Johansson in
Google Scholar
PubMed
Close
,
Claes Ohlsson Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute for Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Search for other papers by Claes Ohlsson in
Google Scholar
PubMed
Close
,
H Herschel Conaway Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

Search for other papers by H Herschel Conaway in
Google Scholar
PubMed
Close
,
Petra Henning Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute for Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Search for other papers by Petra Henning in
Google Scholar
PubMed
Close
, and
Ulf H Lerner Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute for Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Search for other papers by Ulf H Lerner in
Google Scholar
PubMed
Close

Excess vitamin A has been associated with decreased cortical bone thickness and increased fracture risk. While most studies in rodents have employed high dosages of vitamin A for short periods of time, we investigated the bone phenotype in mice after longer exposure to more clinically relevant doses. For 1, 4 and 10 weeks, mice were fed a control diet (4.5 µg retinyl acetate/g chow), a diet modeled from the human upper tolerable limit (UTL; 20 µg retinyl acetate/g chow) and a diet three times UTL (supplemented; 60 µg retinyl acetate/g chow). Time-dependent decreases in periosteal circumference and bone mineral content were noted with the supplemented dose. These reductions in cortical bone resulted in a significant time-dependent decrease of predicted strength and a non-significant trend toward reduced bone strength as analyzed by three-point bending. Trabecular bone in tibiae and vertebrae remained unaffected when vitamin A was increased in the diet. Dynamic histomorphometry demonstrated that bone formation was substantially decreased after 1 week of treatment at the periosteal site with the supplemental dose. Increasing amount of vitamin A decreased endocortical circumference, resulting in decreased marrow area, a response associated with enhanced endocortical bone formation. In the presence of bisphosphonate, vitamin A had no effect on cortical bone, suggesting that osteoclasts are important, even if effects on bone resorption were not detected by osteoclast counting, genes in cortical bone or analysis of serum TRAP5b and CTX. In conclusion, our results indicate that even clinically relevant doses of vitamin A have a negative impact on the amount of cortical bone.

Open access